Skip to main content
Top
Published in: Breast Cancer Research 1/2007

Open Access 01-02-2007 | Research article

Oestrogen receptor negative breast cancers exhibit high cytokine content

Authors: Carine Chavey, Frédéric Bibeau, Sophie Gourgou-Bourgade, Sandrine Burlinchon, Florence Boissière, Daniel Laune, Sylvie Roques, Gwendal Lazennec

Published in: Breast Cancer Research | Issue 1/2007

Login to get access

Abstract

Introduction

An emerging hypothesis suggests that cytokines could play an important role in cancer as potential modulators of angiogenesis and leucocyte infiltration.

Methods

A novel multiplexed flow cytometry technology was used to measure the expression of 17 cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 [p70], IL-13, IL-17, granulocyte colony-stimulating factor [CSF], granulocyte-macrophage CSF, IFN-γ, monocyte chemoattractant protein [MCP]-1, macrophage inflammatory protein [MIP]-1β, tumour necrosis factor [TNF]-α) at the protein level in 105 breast carcinoma. B lymphocyte, T lymphocyte and macrophage levels were determined by immunohistochemistry.

Results

Fourteen of the 17 cytokines were expressed in breast carcinoma, whereas only nine cytokines could be detected in normal breast. Most cytokines were more abundant in breast carcinoma than in normal breast, with IL-6, IL-8, granulocyte CSF, IFN-γ, MCP-1 and MIP-1β being very abundant. IL-2, IL-6, IL-8, IL-10, IFN-γ, MCP-1, MIP-1β and TNF-α, and to a lesser extent IL-1β and IL-13 exhibited levels of expression that were inversely correlated to oestrogen receptor and progesterone receptor status. Most cytokines were not correlated with age at cancer diagnosis, tumour size, histological type, or lymph node status. However, IL-1β, IL-6, IL-8, IL-10, IL-12, MCP-1 and MIP-1β were more abundant in high-grade tumours than in low-grade tumours. In addition, IL-8 and MIP-1β were expressed to a greater degree in HER2-positive than in HER2-negative patients. The expression of most of the studied cytokines was correlated to levels of activator protein-1, which is known to regulate numerous cytokines. Overexpression of MCP-1 and MIP-1β were linked to B lymphocyte, T lymphocyte and macrophage infiltration, whereas high levels of IL-8 were correlated with high macrophage content in tumour. Moreover, IL-8 positive tumours exhibited increased vascularization.

Conclusion

We found that multiple cytokines were overexpressed in oestrogen receptor negative breast carcinoma, and that the three major cytokines – MCP-1, MIP-1β and IL-8 – were correlated with inflammatory cell component, which could account for the aggressiveness of these tumours.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.CrossRefPubMed
2.
go back to reference Skoog L, Humla S, Axelsson M, Frost M, Norman A, Nordenskjold B, Wallgren A: Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy. Acta Oncol. 1987, 26: 95-100.CrossRefPubMed Skoog L, Humla S, Axelsson M, Frost M, Norman A, Nordenskjold B, Wallgren A: Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy. Acta Oncol. 1987, 26: 95-100.CrossRefPubMed
3.
go back to reference McGuire WL: Endocrine therapy of breast cancer. Annu Rev Med. 1975, 26: 353-363. 10.1146/annurev.me.26.020175.002033.CrossRefPubMed McGuire WL: Endocrine therapy of breast cancer. Annu Rev Med. 1975, 26: 353-363. 10.1146/annurev.me.26.020175.002033.CrossRefPubMed
4.
go back to reference Wilson J, Balkwill F: The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol. 2002, 12: 113-120. 10.1006/scbi.2001.0419.CrossRefPubMed Wilson J, Balkwill F: The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol. 2002, 12: 113-120. 10.1006/scbi.2001.0419.CrossRefPubMed
5.
go back to reference Boon T, Van den Eynde B: Tumour immunology. Curr Opin Immunol. 2003, 15: 129-130. 10.1016/S0952-7915(03)00010-4.CrossRefPubMed Boon T, Van den Eynde B: Tumour immunology. Curr Opin Immunol. 2003, 15: 129-130. 10.1016/S0952-7915(03)00010-4.CrossRefPubMed
6.
go back to reference Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S: CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 2004, 25: 201-209. 10.1016/j.it.2004.02.006.CrossRefPubMed Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S: CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 2004, 25: 201-209. 10.1016/j.it.2004.02.006.CrossRefPubMed
7.
go back to reference Elenkov IJ, Chrousos GP: Stress hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol Metab. 1999, 10: 359-368. 10.1016/S1043-2760(99)00188-5.CrossRefPubMed Elenkov IJ, Chrousos GP: Stress hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol Metab. 1999, 10: 359-368. 10.1016/S1043-2760(99)00188-5.CrossRefPubMed
8.
go back to reference Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G: IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene. 2003, 22: 256-265. 10.1038/sj.onc.1206113.CrossRefPubMedPubMedCentral Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G: IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene. 2003, 22: 256-265. 10.1038/sj.onc.1206113.CrossRefPubMedPubMedCentral
9.
go back to reference Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957, 11: 359-377.CrossRefPubMedPubMedCentral Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957, 11: 359-377.CrossRefPubMedPubMedCentral
10.
go back to reference Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, Vignon F, Lazennec G: Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene. 2004, 23: 6105-6114. 10.1038/sj.onc.1207815.CrossRefPubMedPubMedCentral Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, Vignon F, Lazennec G: Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene. 2004, 23: 6105-6114. 10.1038/sj.onc.1207815.CrossRefPubMedPubMedCentral
11.
go back to reference Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer. 1999, 84: 533-538. 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J.CrossRefPubMed Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer. 1999, 84: 533-538. 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J.CrossRefPubMed
12.
go back to reference Green AR, Green VL, White MC, Speirs V: Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer. 1997, 72: 937-941. 10.1002/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0.CO;2-Q.CrossRefPubMed Green AR, Green VL, White MC, Speirs V: Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer. 1997, 72: 937-941. 10.1002/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0.CO;2-Q.CrossRefPubMed
13.
go back to reference Venetsanakos E, Beckman I, Bradley J, Skinner JM: High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer. 1997, 75: 1826-1830.CrossRefPubMedPubMedCentral Venetsanakos E, Beckman I, Bradley J, Skinner JM: High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer. 1997, 75: 1826-1830.CrossRefPubMedPubMedCentral
14.
go back to reference Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003, 48: 82-84.PubMed Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003, 48: 82-84.PubMed
15.
go back to reference Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY: Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002, 2: 311-315.CrossRefPubMed Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY: Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002, 2: 311-315.CrossRefPubMed
16.
go back to reference Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF: HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006, 25: 6986-6996. 10.1038/sj.onc.1209685.CrossRefPubMed Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF: HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006, 25: 6986-6996. 10.1038/sj.onc.1209685.CrossRefPubMed
17.
go back to reference Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al: Expression of interleukin-1beta in human breast carcinoma. Cancer. 1997, 80: 421-434. 10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z.CrossRefPubMed Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al: Expression of interleukin-1beta in human breast carcinoma. Cancer. 1997, 80: 421-434. 10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z.CrossRefPubMed
18.
go back to reference Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, Huang RP: Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer. 2004, 109: 507-515. 10.1002/ijc.11724.CrossRefPubMed Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, Huang RP: Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer. 2004, 109: 507-515. 10.1002/ijc.11724.CrossRefPubMed
19.
go back to reference Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G, Kreutzer DL: The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol. 2003, 23: 269-284.PubMed Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G, Kreutzer DL: The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol. 2003, 23: 269-284.PubMed
20.
go back to reference Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Lindquist R, Barrows G, Kreutzer DL: Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000, 18: 293-302.CrossRefPubMed Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Lindquist R, Barrows G, Kreutzer DL: Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000, 18: 293-302.CrossRefPubMed
21.
go back to reference Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M, Czerwenka K, Schreiber M, Seifert M, Kubista E: Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res. 2003, 9: 4877-4883.PubMed Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M, Czerwenka K, Schreiber M, Seifert M, Kubista E: Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res. 2003, 9: 4877-4883.PubMed
22.
go back to reference Chiu JJ, Sgagias MK, Cowan KH: Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res. 1996, 2: 215-221.PubMed Chiu JJ, Sgagias MK, Cowan KH: Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res. 1996, 2: 215-221.PubMed
23.
go back to reference Galien R, Garcia T: Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. 1997, 25: 2424-2429. 10.1093/nar/25.12.2424.CrossRefPubMedPubMedCentral Galien R, Garcia T: Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. 1997, 25: 2424-2429. 10.1093/nar/25.12.2424.CrossRefPubMedPubMedCentral
24.
go back to reference Pfeilschifter J, Koditz R, Pfohl M, Schatz H: Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002, 23: 90-119. 10.1210/er.23.1.90.CrossRefPubMed Pfeilschifter J, Koditz R, Pfohl M, Schatz H: Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002, 23: 90-119. 10.1210/er.23.1.90.CrossRefPubMed
25.
go back to reference McMurray RW, Ndebele K, Hardy KJ, Jenkins JK: 17-beta-estradiol suppresses IL-2 and IL-2 receptor. Cytokine. 2001, 14: 324-333. 10.1006/cyto.2001.0900.CrossRefPubMed McMurray RW, Ndebele K, Hardy KJ, Jenkins JK: 17-beta-estradiol suppresses IL-2 and IL-2 receptor. Cytokine. 2001, 14: 324-333. 10.1006/cyto.2001.0900.CrossRefPubMed
26.
go back to reference Carruba G, D'Agostino P, Miele M, Calabro M, Barbera C, Bella GD, Milano S, Ferlazzo V, Caruso R, Rosa ML, et al: Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells. J Cell Biochem. 2003, 90: 187-196. 10.1002/jcb.10607.CrossRefPubMed Carruba G, D'Agostino P, Miele M, Calabro M, Barbera C, Bella GD, Milano S, Ferlazzo V, Caruso R, Rosa ML, et al: Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells. J Cell Biochem. 2003, 90: 187-196. 10.1002/jcb.10607.CrossRefPubMed
27.
go back to reference Salem ML: Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr Drug Targets Inflamm Allergy. 2004, 3: 97-104. 10.2174/1568010043483944.CrossRefPubMed Salem ML: Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr Drug Targets Inflamm Allergy. 2004, 3: 97-104. 10.2174/1568010043483944.CrossRefPubMed
28.
go back to reference Curran EM, Judy BM, Newton LG, Lubahn DB, Rottinghaus GE, Macdonald RS, Franklin C, Estes DM: Dietary soy phytoestrogens and ERalpha signalling modulate interferon gamma production in response to bacterial infection. Clin Exp Immunol. 2004, 135: 219-225. 10.1111/j.1365-2249.2003.02368.x.CrossRefPubMedPubMedCentral Curran EM, Judy BM, Newton LG, Lubahn DB, Rottinghaus GE, Macdonald RS, Franklin C, Estes DM: Dietary soy phytoestrogens and ERalpha signalling modulate interferon gamma production in response to bacterial infection. Clin Exp Immunol. 2004, 135: 219-225. 10.1111/j.1365-2249.2003.02368.x.CrossRefPubMedPubMedCentral
29.
go back to reference Nakaya M, Yamasaki M, Miyazaki Y, Tachibana H, Yamada K: Estrogenic compounds suppressed interferon-gamma production in mouse splenocytes through direct cell-cell interaction. In Vitro Cell Dev Biol Anim. 2003, 39: 383-387. 10.1290/1543-706X(2003)039<0383:ECSIPI>2.0.CO;2.CrossRefPubMed Nakaya M, Yamasaki M, Miyazaki Y, Tachibana H, Yamada K: Estrogenic compounds suppressed interferon-gamma production in mouse splenocytes through direct cell-cell interaction. In Vitro Cell Dev Biol Anim. 2003, 39: 383-387. 10.1290/1543-706X(2003)039<0383:ECSIPI>2.0.CO;2.CrossRefPubMed
30.
go back to reference Kanda N, Watanabe S: 17Beta-estradiol inhibits MCP-1 production in human keratinocytes. J Invest Dermatol. 2003, 120: 1058-1066. 10.1046/j.1523-1747.2003.12255.x.PubMed Kanda N, Watanabe S: 17Beta-estradiol inhibits MCP-1 production in human keratinocytes. J Invest Dermatol. 2003, 120: 1058-1066. 10.1046/j.1523-1747.2003.12255.x.PubMed
31.
go back to reference Fanti P, Nazareth M, Bucelli R, Mineo M, Gibbs K, Kumin M, Grzybek K, Hoeltke J, Raiber L, Poppenberg K, et al: Estrogen decreases chemokine levels in murine mammary tissue: implications for the regulatory role of MIP-1 alpha and MCP-1/JE in mammary tumor formation. Endocrine. 2003, 22: 161-168. 10.1385/ENDO:22:2:161.CrossRefPubMed Fanti P, Nazareth M, Bucelli R, Mineo M, Gibbs K, Kumin M, Grzybek K, Hoeltke J, Raiber L, Poppenberg K, et al: Estrogen decreases chemokine levels in murine mammary tissue: implications for the regulatory role of MIP-1 alpha and MCP-1/JE in mammary tumor formation. Endocrine. 2003, 22: 161-168. 10.1385/ENDO:22:2:161.CrossRefPubMed
32.
go back to reference Davies S, Dai D, Wolf DM, Leslie KK: Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells. J Soc Gynecol Investig. 2004, 11: 494-499. 10.1016/j.jsgi.2004.04.003.CrossRefPubMed Davies S, Dai D, Wolf DM, Leslie KK: Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells. J Soc Gynecol Investig. 2004, 11: 494-499. 10.1016/j.jsgi.2004.04.003.CrossRefPubMed
33.
go back to reference Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM: Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab. 1999, 84: 4055-4061. 10.1210/jc.84.11.4055.PubMed Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM: Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab. 1999, 84: 4055-4061. 10.1210/jc.84.11.4055.PubMed
34.
go back to reference Loudon JA, Elliott CL, Hills F, Bennett PR: Progesterone represses interleukin-8 and cyclo-oxygenase-2 in human lower segment fibroblast cells and amnion epithelial cells. Biol Reprod. 2003, 69: 331-337. 10.1095/biolreprod.102.013698.CrossRefPubMed Loudon JA, Elliott CL, Hills F, Bennett PR: Progesterone represses interleukin-8 and cyclo-oxygenase-2 in human lower segment fibroblast cells and amnion epithelial cells. Biol Reprod. 2003, 69: 331-337. 10.1095/biolreprod.102.013698.CrossRefPubMed
35.
go back to reference Kelly RW, Carr GG, Riley SC: The inhibition of synthesis of a beta-chemokine, monocyte chemotactic protein-1 (MCP-1) by progesterone. Biochem Biophys Res Commun. 1997, 239: 557-561. 10.1006/bbrc.1997.7502.CrossRefPubMed Kelly RW, Carr GG, Riley SC: The inhibition of synthesis of a beta-chemokine, monocyte chemotactic protein-1 (MCP-1) by progesterone. Biochem Biophys Res Commun. 1997, 239: 557-561. 10.1006/bbrc.1997.7502.CrossRefPubMed
36.
go back to reference Fujimoto J, Sakaguchi H, Aoki I, Tamaya T: Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 2000, 60: 2632-2601.PubMed Fujimoto J, Sakaguchi H, Aoki I, Tamaya T: Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 2000, 60: 2632-2601.PubMed
37.
go back to reference Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000, 6: 3282-3289.PubMed Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000, 6: 3282-3289.PubMed
38.
go back to reference Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer. 2001, 92: 1085-1091. 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K.CrossRefPubMed Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer. 2001, 92: 1085-1091. 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K.CrossRefPubMed
Metadata
Title
Oestrogen receptor negative breast cancers exhibit high cytokine content
Authors
Carine Chavey
Frédéric Bibeau
Sophie Gourgou-Bourgade
Sandrine Burlinchon
Florence Boissière
Daniel Laune
Sylvie Roques
Gwendal Lazennec
Publication date
01-02-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1648

Other articles of this Issue 1/2007

Breast Cancer Research 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine